Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MNI-792

Radiopharmaceutical · developed by Takeda

Phase 1 Most advanced trial (none active)
TAK Developer
1 Registered trials

What is MNI-792?

MNI-792 is an investigational radiopharmaceutical studied in Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents.

At a glance

Drug type
Radiopharmaceutical
Therapy area
Neurology
Developer
Takeda (TAK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02497235 Phase 1 Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents Completed TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

More from Takeda

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 Mezagitamab Phase 3 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2 TAK-188 Phase 1/2

Follow TAK, the company behind MNI-792

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.